1.血管相关细胞对肿瘤发展的影响及其转化研究。实验血液学国家重点实验室开放课题（启动资金，2019-）。

代表著作38篇（第一作者或通讯作者）

一．特邀专家评述代表著作（10篇）

1.     Cao Y. Detrimental effects of anti-VEGF-basedantiangiogenic cancer drugs on endocrinesystem. NatureReview Endocrinology, 2014 Sep;10(9):530-9. doi:

10.1038/nrendo.2014.114.Epub 2014 Jul 22.

2.        Cao Y. Multifarious functions of the PDGF system inmodulation of angiogenesis, vascularintegrity, tumor growth and metastasis, Trendsin Molecular Medicine.

Aug;19(8):460-73.2013.

3.     Cao YH. Off-tumor target-beneficial site forantiangiogenic cancer therapy? Nature Rev Clin Oncol. 2010;7:604-608

4.     Cao Y, Langer R. Optimizing the delivery of cancer drugsthat block angiogenesis. ScienceTransl Med. 2010;2:15ps13

5.     Cao Y. Adipose tissue angiogenesis as a therapeutictarget for obesity and metabolic diseases. Nature Rev DrugDiscov. 2010;9:107-115

6.     Cao Y. Wake-up call for endothelial cells. Blood.2010;115:2336-2337

7.     Cao Y, Langer R. A review of Judah Folkman's remarkableachievements in biomedicine.Proc Natl Acad Sci U S A. 2008;105:13203-13205

8.        Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest.

2007;117:2362-2368

9.        Cao YH. VEGF calls its receptors from the recyclingcompartment. Blood.

2006;108:2506-2507

10.  Cao Y. Opinion: Emerging mechanisms oftumourlymphangiogenesis and lymphatic metastasis. Nature Rev Cancer. 2005;5:735-743

二．研究论文代表著作（28篇）

1.     Adipocyte and Lipid Metabolism in Cancer Drug Resistance. J ClinInvest. 2019 Jul 2;129(8):3006-3017.

2.     Bladder drug mirabegron exacerbates atherosclerosisthrough activation of brown fat-mediated lipolysis. ProcNatlAcadSci U S A. 2019May28;116(22):10937-10942.

3.     Endothelial lifediscontinues without Erk. J Exp Med. 2019 Aug 5;216(8):1730-1732.

4.     Ablation ofendothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissuebrowning. J Exp Med. 2018 Feb 5;215(2):611-626.

5.     A Novel Concept of the Smart NIR-Light-Controlled DrugReleaseof Black Phosphorus Nanostructure for Cancer Therapy. ProcNatlAcadSciU S A. 2018 Jan 16;115(3):501-506.

6.     Obesity Protects Cancerfrom Drugs Targeting Blood Vessels. Cell Metab. 2018Jun 5;27(6):1163-1165.

7.     Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. CellMetab.2018 Jul 3;28(1):104-117.e5.

8.     Off-tumor targets confer antiangiogenicdrug resistance byinducing erythropoietin production in the host macroenvironment. ProcNatlAcadSciU S A. 2017 Nov 7;114(45):E9635-E9644..

9.     A zebrafish model discovers a novelmechanism of stromalfibroblast-mediated cancer metastasis. ClinicalCancer Res. 2017Apr 18. pii: clincanres.0101.2017. doi:10.1158/1078-0432.CCR-17-0101. 2017

10.  Discontinuation of anti-VEGF cancer therapy promotesmetastasis through a liverrevascularization mechanism, NatureCommunications, 1;7:12680., 2016

11.  Endothelial PDGF-CC MediatesAngiogenesis-DependentThermogenesis in Browning Fat. NatureCommunications,7:12152., 2016

12.  The PDGF-BB-SOX7 axis-modulated IL-33 in pericytesandstromal cells promotes metastasis through tumour-associated macrophages. NatureCommunications,2016 May 6;7:11385. doi: 10.1038/ncomms11385.

13.  Modulation of age-related insulin sensitivity by VEGF-dependentvascular plasticity inadipose tissues. ProcNatl Acad Sci U S A. 2014 Sep 30. pii: 201415825, 2014

14.  TNFR1-mediates TNF-á-induced tumorinflammatorylymphangiogenesis and lymphatic metastasis by orchestrating the VEGF-C-–VEGFR3signaling pathway, Nature Communications, | 5:4944 |DOI:10.1038/ncomms5944 |2014

15.  Opposing effectsof anti-PDGF drug-induced metastasis. NatureCommunication. 8;4:2129, 2013.

16.  PDGF-B modulates hematopoiesis and tumor angiogenesis byswitchingon hypoxia-independent but ATF3-dependent erythropoietin production instromal cells.Nature Medicine.; Dec 4;18(1):100-10 2011

17.  Mouse corneallymphangiogenesis model. Nature Protoc. 2011;Jun;6(6):817-26.

18.  Hypoxia-induced retinopathy model in adult zebrafish. Nature Protoc. 2010;5:1903- 1910

19.  Angiogenic factors FGF2 and PDGF-BB synergisticallypromote murine tumorneovascularization and metastasis. J Clin Invest. 2007;117:2766-2777

20.  Presence of bone marrow- derivedcirculating progenitorendothelial cells in the newly formed lymphatic vessels. Blood.2005;106:4184-4190

21.  PDGF-BB induces intratumorallymphangiogenesis andpromotes lymphatic metastasis. Cancer Cell. 2004;6:333-345

22.  Angiogenic synergism, vascular stability and improvementof hind-limb ischemia by acombination of PDGF-BB and FGF-2. Nature Med. 2003;9:604-613

23.  Placenta growth factor-1 antagonizes VEGF-inducedangiogenesis andtumor growth by the formation of functionally inactivePlGF-1/VEGF heterodimers.Cancer Cell. 2002;1:99-108

24.   Cao Y, Cao R.Angiogenesis inhibited by drinking tea. Nature. 1999;398:381

25.  Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, FolkmanJ. Expression of angiostatincdna in a murine fibrosarcoma suppresses primarytumor growth and produces long-termdormancy of metastases. J Clin Invest. 1998;101:1055-1063

26.  Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V,Qi JH, Claesson-Welsh L,Alitalo K. Vascular endothelial growth factor C inducesangiogenesis in vivo. Proc NatlAcad Sci U S A. 1998;95:14389-14394

27.  Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivoangiogenic activity and hypoxiainduction of heterodimers of placenta growthfactor/vascular endothelial growth factor. JClin Invest. 1996;98:2507-2511

28.  Cao Y, Chen C, Weatherbee JA, Tsang M, Folkman J.Gro-beta, a -c-x-c- chemokine, is anangiogenesis inhibitor that suppresses thegrowth of lewis lung carcinoma in mice. J ExpMed. 1995;182:2069-2077